Defective proteostasis in celiac disease as a new therapeutic target
Open Access
- 8 February 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 10 (2), 1-7
- https://doi.org/10.1038/s41419-019-1392-9
Abstract
Cystic fibrosis (CF) is a disease caused by loss-of-function mutations affecting the CF transmembrane conductance regulator (CFTR), a chloride channel. Recent evidence indicates that CFTR is inhibited by a gluten/gliadin-derived peptide (P31-43), causing an acquired state of CFTR inhibition within the gut that contributes to the pathogenesis of celiac disease (CD). Of note, CFTR inhibition does not only cause intra-and extracellular ion imbalances but also affects proteostasis by activating transglutaminase-2 (TGM2) and by disabling autophagy. These three phenomena (CFTR inhibition, TGM2 activation, and autophagy impairment) engage in multiple self-amplifying circuitries, thus forming an "infernal trio". The trio hinders enterocytes from returning to homeostasis and instead locks them in an irreversible pro-inflammatory state that ultimately facilitates T lymphocyte-mediated immune responses against another gluten/gliadin-derived peptide (P57-68), which, upon deamidation by activated TGM2, becomes fully antigenic. Hence, the pathogenic protein gliadin exemplifies a food constituent the exceptional immunogenicity of which arises from a combination of antigenicity (conferred by deaminated P57-68) and adjuvanticity (conferred by P31-43). CF can be treated by agents targeting the "infernal trio" including CFTR potentiators, TGM2 inhibitors, and autophagy enhancers. We speculate that such agents may also be used for CD therapy and indeed could constitute close-to-etiological treatments of this enteropathy.Keywords
This publication has 68 references indexed in Scilit:
- Triggers and drivers of autoimmunity: lessons from coeliac diseaseNature Reviews Immunology, 2013
- Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR DefectFrontiers in Pharmacology, 2013
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Mitochondria and the Autophagy–Inflammation–Cell Death Axis in Organismal AgingScience, 2011
- Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigensNature, 2011
- Classification and management of refractory coeliac diseaseGut, 2010
- Crosstalk between apoptosis and autophagy within the Beclin 1 interactomeThe EMBO Journal, 2010
- Cystic fibrosisThe Lancet, 2009
- Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesisMucosal Immunology, 2009
- Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1The EMBO Journal, 2007